The Beauty Health Company (NASDAQ:SKIN) Receives Consensus Rating of “Reduce” from Brokerages

Shares of The Beauty Health Company (NASDAQ:SKIN) have received a consensus recommendation of “Reduce” from the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.50.

SKIN has been the topic of several recent research reports. TD Cowen boosted their price objective on shares of Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a research report on Wednesday, March 13th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 price objective (up from $3.00) on shares of Beauty Health in a research report on Wednesday, March 13th. DA Davidson reiterated a “buy” rating and issued a $5.00 price objective on shares of Beauty Health in a research report on Friday, March 15th. Piper Sandler reiterated an “underweight” rating and issued a $3.00 price objective (up from $2.00) on shares of Beauty Health in a research report on Wednesday, March 13th. Finally, Canaccord Genuity Group boosted their price objective on shares of Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research report on Thursday, March 14th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. 180 Wealth Advisors LLC increased its stake in shares of Beauty Health by 14.9% during the 1st quarter. 180 Wealth Advisors LLC now owns 81,285 shares of the company’s stock valued at $361,000 after acquiring an additional 10,566 shares during the last quarter. Sierra Summit Advisors LLC acquired a new position in shares of Beauty Health during the 4th quarter valued at about $856,000. Price T Rowe Associates Inc. MD increased its stake in shares of Beauty Health by 38.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,347 shares of the company’s stock valued at $216,000 after acquiring an additional 19,150 shares during the last quarter. Barclays PLC increased its stake in shares of Beauty Health by 48.0% during the 4th quarter. Barclays PLC now owns 139,507 shares of the company’s stock valued at $433,000 after acquiring an additional 45,220 shares during the last quarter. Finally, Numerai GP LLC acquired a new position in shares of Beauty Health during the 4th quarter valued at about $567,000. 93.26% of the stock is currently owned by hedge funds and other institutional investors.

Beauty Health Price Performance

Shares of NASDAQ SKIN opened at $3.27 on Friday. The firm has a market capitalization of $403.62 million, a P/E ratio of -4.25 and a beta of 1.01. Beauty Health has a one year low of $1.35 and a one year high of $13.90. The company’s fifty day moving average is $3.65 and its two-hundred day moving average is $3.48. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.28 and a current ratio of 6.07.

Beauty Health (NASDAQ:SKIN) last issued its earnings results on Tuesday, March 12th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. Beauty Health had a negative net margin of 25.65% and a negative return on equity of 18.85%. The company had revenue of $96.80 million for the quarter, compared to analyst estimates of $87.22 million. During the same period in the previous year, the firm earned $0.03 EPS. The business’s revenue was down 1.3% on a year-over-year basis. Analysts forecast that Beauty Health will post -0.1 EPS for the current fiscal year.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.